GC
RCUS icon

Guggenheim Capital’s Arcus Biosciences RCUS Stock Holding History

Guggenheim Capital’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-9,903
Closed -$251K – 2019
2022
Q2 		$251K Buy
+9,903
New +$243K ﹤0.01% 1851

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Guggenheim Capital's RCUS Position: Q3 2022 in Review

Guggenheim Capital sold out of Arcus Biosciences (RCUS) in Q3 2022, closing a stake of 9,903 shares — an estimated $251K sold.

Guggenheim Capital first reported a position in RCUS in Q2 2022 and held it in 1 quarter. The position peaked at $251K in Q2 2022. 184 funds tracked by Wall St. Rank hold RCUS as of Q3 2022.

  • Guggenheim Capital reported no remaining Arcus Biosciences position as of Q3 2022 after selling out during the quarter.
  • Guggenheim Capital sold 9,903 Arcus Biosciences shares in Q3 2022, an estimated $251K.
  • Guggenheim Capital first reported a position in Arcus Biosciences in Q2 2022 and held it in 1 quarter.
  • Guggenheim Capital's Arcus Biosciences position peaked at $251K in Q2 2022.
  • 184 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2022.

Based on Guggenheim Capital's 13F filing for Q3 2022, filed 14 Nov 2022.